Ortho Evra Birth Control PatchCMHT is investigating blood clots—including those starting in the legs (deep vein thrombosis), that can move to the heart, brain, or lungs causing debilitating and sometimes fatal heart attacks, strokes, and pulmonary embolisms—linked to use of the Ortho Evra Birth Control Patch manufactured by Ortho McNeil Pharmaceuticals, a Johnson & Johnson subsidiary. The only birth control patch on the market, the FDA approved the Ortho Evra patch in November 2001. In November 2005, Ortho McNeil and the FDA added important warnings to the drug’s labeling, including the alarming news that, following absorption through the skin into the bloodstream, the Ortho Evra patch, on average, exposes women to 60 percent more estrogen than a typical birth control pill. Such excessive estrogen levels may explain reports that women using the Ortho Evra patch suffer life-threatening blood clots at rates many times higher than women using traditional birth control pills. Cohen Milstein has filed several cases in New Jersey. If you believe that you or a loved one has suffered a heart attack, stroke, pulmonary embolism, deep vein thrombosis, or other serious condition caused by a blood clot as a result of using the Ortho Evra patch, please contact us so that we may evaluate your case: 1-877-582-1156, lawinfo@cmht.com, fax (202-408-4699) or U.S. mail (1100 New York Ave., Ste 500W, Washington, DC, 20005). |
